Suppression of secondary antibody response by intravenous immunoglobulin and development of tolerance in a patient with haemophilia B and antibodies.
D000328:Adult; D000906:Antibodies / Q000032:analysis*; D000917:Antibody Formation / Q000187:drug effects*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005164:Factor IX / Q000276:immunology* / Q000627:therapeutic use; D002836:Hemophilia B / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects*; D007074:Immunoglobulin G / Q000008:administration & dosage*; D007263:Infusions, Parenteral; D008297:Male
D000906:Antibodies; D007074:Immunoglobulin G; D003520:Cyclophosphamide; D005164:Factor IX